A single B-repeat of Staphylococcus epidermidis accumulation- associated protein induces protective immune responses in an experimental biomaterial-associated infection mouse model

Clinical and Vaccine Immunology

Volumn 21, Issue 9, 2014, Pages 1206-1214

  Yan, Lin ^a   Zhang, Lei ^a   Ma, Hongyan ^a,b   Chiu, David ^a   Bryers, James D ^a,b  

^a University of Washington   (United States)

^b University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; FREUND ADJUVANT; IMMUNOGLOBULIN G ANTIBODY; OVALBUMIN; RECOMBINANT BRPT1.0 PROTEIN VACCINE; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BIOFILM; COLONY FORMING UNIT; COMPOSITE MATERIAL; CONTROLLED STUDY; DEVICE INFECTION; DOSE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG STRUCTURE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFECTION RESISTANCE; MOUSE; NONHUMAN; POROSITY; PRIORITY JOURNAL; PROTEIN DOMAIN; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; WEIGHT CHANGE; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; PATHOLOGY; PROCEDURES; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED STATES; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BIOCOMPATIBLE MATERIALS; DISEASE MODELS, ANIMAL; FEMALE; FREUND'S ADJUVANT; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MICE, INBRED C57BL; PROSTHESIS-RELATED INFECTIONS; RECOMBINANT PROTEINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT OUTCOME; UNITED STATES; VACCINATION; VACCINES, SYNTHETIC;

EID: 84933674866     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00306-14     Document Type: Article

References (38)

1. Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM. 2007. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 122:160-166. http://www.ncbi.nlm.nih.gov/ pmc/articles/PMC1820440/.
2. Douglas AR, Ii S. 2009. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. CDC, Atlanta, GA.
3. O'Gara JP, Humphreys H. 2001. Staphylococcus epidermidis biofilms: importance and implications. J. Med. Microbiol. 50:582-587. http://www.ncbi.nlm. nih.gov/pubmed/11444767. (Pubitemid 32588152)
4. Otto M. 2009. Staphylococcus epidermidis - the "accidental" pathogen. Nat. Rev. Microbiol. 7:555-567. http://dx.doi.org/10.1038/nrmicro2182.
5. Vuong C, Otto M. 2002. Staphylococcus epidermidis infections. Microbes Infect. 4:481-489. http://dx.doi.org/10.1016/S1286-4579(02)01563-0. (Pubitemid 34270685)
6. Lautenbach E. 2001. Chapter 14, Impact of changes in antibiotic use practices on nosocomial infections and antimicrobial resistance - Clostridium difficile and vancomycin-resistant Enterococcus (VRE). In Shojania KG, Duncan BW, McDonald KM, Wachter RM (ed), Making health care safer: a critical analysis of patient safety practices, evidence report/technology assessment, no. 43. Contract 290-97-0013. Agency for Healthcare Research and Quality, Rockville, MD.
7. Costerton JW. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx.doi.org/10.1126/science.284.5418. 1318. (Pubitemid 29289651)
8. Shahrooei M. 2010. Identification of potential targets for vaccination against Staphylococcus epidermidis biofilms. Ph.D. thesis. University of Leuven, Leuven, Belgium.
9. Mack D, Davies AP, Harris LG, Knobloch JKM, Rohde H. 2009. Staphylococcus epidermidis biofilms: functional molecules, relation to virulence, and vaccine potential. Top. Curr. Chem. 288:157-182. http://dx.doi.org/10.1007/128-2008-19.
10. Shahrooei M, Hira V, Khodaparast L, Khodaparast L, Stijlemans B, Kucharíková S, Burghout P, Hermans PWM, Van Eldere J. 2012. Vaccination with SesC decreases Staphylococcus epidermidis biofilm formation. Infect. Immun. 80:3660-3668. http://dx.doi.org/10.1128/IAI.00104-12.
11. Hussain M, Herrmann M, von Eiff C, Perdreau-Remington F, Peters G. 1997. A 140-kilodalton extracellular protein is essential for the accumulation of Staphylococcus epidermidis strains on surfaces. Infect. Immun. 65: 519-524. (Pubitemid 27053219)
12. Conrady DG, Brescia CC, Horii K, Weiss AA, Hassett DJ, Herr AB. 2008. A zinc-dependent adhesion module is responsible for intercellular adhesion in staphylococcal biofilms. Proc. Natl. Acad. Sci. U. S. A. 105: 19456-19461. http://dx.doi.org/10.1073/pnas.0807717105.
13. Macintosh RL, Brittan JL, Bhattacharya R, Jenkinson HF, Derrick J, Upton M, Handley PS. 2009. The terminal A domain of the fibrillar accumulation- associated protein (Aap) of Staphylococcus epidermidis mediates adhesion to human corneocytes. J. Bacteriol. 191:7007-7016. http://dx.doi.org/10.1128/JB. 00764-09.
14. Rohde H, Burandt EC, Siemssen N, Frommelt L, Burdelski C, Wurster S, Scherpe S, Davies AP, Harris LG, Horstkotte MA, Knobloch JK-M, Ragunath C, Kaplan JB, Mack D. 2007. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of Staphylococcus epidermidis and Staphylococcus aureus isolated from prosthetic hip and knee joint infections. Biomaterials 28:1711-1720. http://dx.doi.org/10.1016/j.biomaterials.2006.11.046. (Pubitemid 46098967)
15. Rohde H, Burdelski C, Bartscht K, Hussain M, Buck F, Horstkotte MA, Knobloch JKM, Heilmann C, Herrmann M, Mack D. 2005. Induction of Staphylococcus epidermidis biofilm formation via proteolytic processing of the accumulation-associated protein by staphylococcal and host proteases. Mol. Microbiol. 55:1883-1895. http://dx.doi.org/10.1111/j.1365-2958.2005.04515.x. (Pubitemid 40445220)
16. Conrady DG, Wilson JJ, Herr AB. 2013. Structural basis for Zn 2+-dependent intercellular adhesion in staphylococcal biofilms. Proc. Natl. Acad. Sci. U. S. A. 110:E202-E211. http://dx.doi.org/10.1073/pnas. 1208134110.
17. Gruszka DT, Wojdyla JA, Bingham RJ, Turkenburg JP, Manfield IW, Steward A, Leech AP, Geoghegan JA, Foster TJ, Clarke J, Potts JR. 2012. Staphylococcal biofilm-forming protein has a contiguous rod-like structure. Proc. Natl. Acad. Sci. U. S. A. 109:E1011-E1018. http://dx.doi.org/10.1073/pnas.1119456109.
18. Bateman A, Holden MTG, Yeats C. 2005. The G5 domain: a potential N-acetylglucosamine recognition domain involved in biofilm formation. Bioinformatics 21:1301-1303. http://dx.doi.org/10.1093/bioinformatics/bti206. (Pubitemid 40542676)
19. Mack D, Davies AP, Harris LG, Jeeves R, Pascoe B, Knobloch JK, Rohde H, Wilkinson TS. 2013. Biomaterials associated infection. Springer, New York, NY.
20. Pourmand MR, Abdossamadi Z, Salari MH, Hosseini M. 2011. Slime layer formation and the prevalence of mecA and aap genes in Staphylococcus epidermidis isolates. J. Infect. Dev. Ctries. 5:34-40. http://dx.doi.org/10.3855/jidc.984.
21. Sun D, Accavitti MA, Bryers JD. 2005. Inhibition of biofilm formation by monoclonal antibodies against Staphylococcus epidermidis RP62A accumulation- associated protein. Clin. Diagn. Lab. Immunol. 12:93-100. http://dx.doi.org/10. 1128/CDLI.12.1.93-100.2005.
22. Gagnon RF, Richards GK. 1993. A mouse model of implant-associated infection. Int. J. Artif. Organs 16:789-798. (Pubitemid 24055461)
23. Gagnon RF, Richards KR, Subang R. 1992. Experimental Staphylococcus epidermidis implant infection in the mouse: kinetics of rifampin and vancomycin action. ASAIO J. 38:596-599.
24. Boelens JJ, Dankert J, Murk JL, Weening JJ, van der Poll T, Dingemans KP, Koole L, Laman JD, Zaat SA. 2000. Biomaterial-associated persistence of Staphylococcus epidermidis in pericatheter macrophages. J. Infect. Dis. 181:1337-1349. http://dx.doi.org/10.1086/315369. (Pubitemid 30252538)
25. Ma H, Darmawan ET, Zhang M, Zhang L, Bryers JD. 2013. Development of a poly(ether urethane) system for the controlled release of two novel anti-biofilm agents based on gallium or zinc and its efficacy to prevent bacterial biofilm formation. J. Control. Release 172:1035-1044. http://dx.doi.org/10.1016/j. jconrel.2013.10.005.
26. Cooper A, Oldinski R, Ma H, Bryers JD, Zhang M. 2013. Chitosan-based nanofibrous membranes for antibacterial filter applications. Carbohydr. Polym. 92:254-259. http://dx.doi.org/10.1016/j.carbpol.2012.08.114.
27. Zhang L, Cao Z, Bai T, Carr L, Ella-Menye J-R, Irvin C, Ratner BD, Jiang S. 2013. Zwitterionic hydrogels implanted in mice resist the foreignbody reaction. Nat. Biotechnol. 31:553-556. http://dx.doi.org/10.1038/nbt.2580.
28. Guo Y, Li J, Hagström E, Ny T. 2008. Protective effects of plasmin(ogen) in a mouse model of Staphylococcus aureus-induced arthritis. Arthritis Rheum. 58:764-772. http://dx.doi.org/10.1002/art.23263. (Pubitemid 351364874)
29. Rossi G, Pengo G, Caldin M, Palumbo Piccionello A, Steiner JM, Cohen ND, Jergens AE, Suchodolski JS. 2014. Comparison of microbiological, histological, and immunomodulatory parameters in response to treatment with either combination therapy with prednisone and metronidazole or probiotic VSL#3 strains in dogs with idiopathic inflammatory bowel disease. PLoS One 9:e94699. http://dx.doi.org/10.1371/journal.pone.0094699.
30. Petrushina I, Tran M, Sadzikava N, Ghochikyan A, Vasilevko V, Agadjanyan MG, Cribbs DH. 2003. Importance of IgG2c isotype in the immune response to β-amyloid in amyloid precursor protein/transgenic mice. Neurosci. Lett. 338:5-8. http://dx.doi.org/10.1016/S0304-3940(02)01357-5. (Pubitemid 36136024)
31. Zhang Z, Goldschmidt T, Salter H. 2012. Possible allelic structure of IgG2a and IgG2c in mice. Mol. Immunol. 50:169-171. http://dx.doi.org/10.1016/j. molimm.2011.11.006.
32. Martin RM, Brady JL, Lew AM. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J. Immunol. Methods 212:187-192. http://dx.doi.org/10.1016/S0022-1759(98)00015-5. (Pubitemid 28288356)
33. Barekzi NA, Felts AG, Poelstra KA, Slunt JB, Grainger DW. 2002. Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against Gram-negative infections. Pharm. Res. 19:1801-1807. http://dx.doi.org/ 10.1023/A:1021481122011. (Pubitemid 36016025)
34. Poelstra KA, Barekzi NA, Rediske AM, Felts AG, Slunt JB, Grainger DW. 2002. Prophylactic treatment of Gram-positive and Gramnegative abdominal implant infections using locally delivered polyclonal antibodies. J. Biomed. Mater. Res. 60: 206 -215. http://dx.doi.org/10.1002/jbm.10069.
35. Poelstra KA, Barekzi NA, Slunt JB, Schuler TC, Grainger DW. 2000. Surgical irrigation with pooled human immunoglobulinGto reduce post-operative spinal implant infection. Tissue Eng. 6:401-411. http://dx.doi.org/10.1089/ 107632700418100. (Pubitemid 30655948)
36. Barekzi NA, Poelstra KA, Felts AG, Rojas IA, Slunt JB, Grainger DW. 1999. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa peritonitis in a murine model. Antimicrob. Agents Chemother. 43:1609-1615. (Pubitemid 29331236)
37. Broekhuizen CAN, de Boer L, Schipper K, Jones CD, Quadir S, Feldman RG, Vandenbroucke-Grauls CMJE, Zaat SAJ. 2009. The influence of antibodies on Staphylococcus epidermidis adherence to polyvinylpyrrolidone- coated silicone elastomer in experimental biomaterial-associated infection in mice. Biomaterials 30:6444-6450. http://dx.doi.org/10.1016/j.biomaterials.2009.08.018.
38. Hu J, Xu T, Zhu T, Lou Q, Wang X, Wu Y, Huang R, Liu J, Liu H, Yu F, Ding B, Huang Y, Tong W, Qu D. 2011. Monoclonal antibodies against accumulation-associated protein affect EPS biosynthesis and enhance bacterial accumulation of Staphylococcus epidermidis. PLoS One 6:e20918. http://dx.doi.org/10.1371/journal.pone.0020918.